Free shipping on all orders over $ 500

XMD8-92

Cat. No. M6089

All AbMole products are for research use only, cannot be used for human consumption.

XMD8-92 Structure
Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 54 In stock
5mg USD 48 In stock
10mg USD 70 In stock
50mg USD 250 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

XMD8-92, via inhibition of BMK1 activation, significantly induces p21 expression in cells, and mediates suppression of cancer cell proliferation. XMD8-92 markedly abrogates the inhibitive effects of hydroxysafflor yellow A (HSYA) on hepatic stellate cell (HSC) activation, and blockes the HSYA-mediated MEF2C down-regulation.

Protocol (for reference only)
Cell Experiment
Cell lines A549 cell lines
Preparation method Control and shBNIP3/shBNIP3L A549 sphere cells were treated with/without 4 μmol/L XMD8-92 for 36 hrs, and collected by trypsinization and centrifugation at 300 G for 5 mins. The resultant cells were washed twice with cold PBS and resuspended in 100 μL Annexin-binding buffer.
Concentrations 4 μmol/L
Incubation time 36 h
Animal Experiment
Animal models Nod/Scid mice bearing HeLa xenograft, C57Bl/6 mice bearing LL/2 xenograft
Formulation
Dosages ~50 mg/kg twice a day
Administration i.p.
Chemical Information
Molecular Weight 474.55
Formula C26H30N6O3
CAS Number 1234480-50-2
Solubility (25°C) DMSO 48 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Park SJ, et al. Cancer Lett. BIX02189 inhibits TGF-β1-induced lung cancer cell metastasis by directly targeting TGF-β type I receptor.

[2] Song C, et al. Oncotarget. Inhibition of BMK1 pathway suppresses cancer stem cells through BNIP3 and BNIP3L.

[3] Sureban SM, et al. Cancer Lett. XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism.

Related ERK Products
SCH772984

SCH772984 is a novel and selective inhibitor of ERK1/2 with IC50 of 4 nM and 1 nM, respectively.

FR 180204

FR 180204 is an ATP-competitive, selective ERK inhibitor with Ki of 0.31 μM and 0.14 μM for ERK1 And ERK2, respectively.

GDC-0994

Ravoxertinib (GDC-0994) is an orally active ERK kinase inhibitor with IC50 of 6.1 nM and 3.1 nM against ERK1 and ERK2, respectively.

Astragaloside IV

Astragaloside IV is a bioactive saponin first isolated from the dried plant roots of the genus Astragalus, which is used in traditional Chinese medicine. It has various effect on the cardiovascular, immune, digestive, and nervous systems.

Corynoxeine

Corynoxeine, isolated from the hook of Uncaria Rhynchophylla, is a potent ERK1/ERK 2 inhibitor in the proliferation of PDGF-BB induced vascular smooth muscle cells (VSMCs).

  Catalog
Abmole Inhibitor Catalog




Keywords: XMD8-92 supplier, ERK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.